1. Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L. (March 2022) Authors: Popat, Sanjay; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James; Han, Ji-Youn; Hochmair, Maximilian; Lee, Ki Hyeong; Delmonte, Angelo; Garcia Campelo, Maria; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander; Gettinger, Scott; Tiseo, Marcello; Lin, Huamao; Liu, Yuy... Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗